Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Do‐Youn Oh et al.|The Lancet Oncology|2023Cited by 614
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal CancerThierry André, Sara Lonardi, Jaafar Bennouna et al.|New England Journal of Medicine|2024Cited by 208